rentosertib (INS018_055) / Insilico Medicine |
NCT05938920: Study Evaluating INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Completed | 2 | 71 | RoW | INS018_055, Placebo | InSilico Medicine Hong Kong Limited | Idiopathic Pulmonary Fibrosis (IPF) | 08/24 | 08/24 | | |
NCT05975983: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 60 | US | INS018_055, Placebo | InSilico Medicine Hong Kong Limited | Idiopathic Pulmonary Fibrosis (IPF) | 02/26 | 02/26 | | |
NCT05154240: A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects |
|
|
| Completed | 1 | 78 | RoW | INS018_055, Placebo | InSilico Medicine Hong Kong Limited | Idiopathic Pulmonary Fibrosis | 12/22 | 12/22 | | |
ISM5411 / Insilico Medicine |
| Completed | 1 | 79 | RoW | ISM5411, Placebo | InSilico Medicine Hong Kong Limited | Healthy Subjects | 09/24 | 09/24 | | |
ISM004-1057D / Insilico Medicine, Fosun Pharma |
NCT06445517: Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma |
|
|
| Recruiting | 1 | 60 | RoW | ISM8207 | InSilico Medicine Hong Kong Limited | Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma | 11/26 | 02/27 | | |
XL309 / Exelixis |
NCT05932862: A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 425 | US | XL309 (ISM3091), Olaparib | Exelixis | Advanced Solid Tumor | 01/29 | 08/29 | | |
ISM3412 / Insilico Medicine |
NCT06414460: Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 80 | US, RoW | ISM3412 | InSilico Medicine Hong Kong Limited | Locally Advanced/Metastatic Solid Tumors | 03/28 | 03/29 | | |
ISM033-154 / Insilico Medicine |
NCT06724042: Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 159 | NA | ISM5939, Cisplatin, Docetaxel, Pembrolizumab | InSilico Medicine Hong Kong Limited | Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors | 12/28 | 12/29 | | |